Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156959 | 0.81 | CES2 (0.50) | CYP3A4CYP17A1CYP11B1CYP11B2CYP2C9 | |
| SCHEMBL12637591 | 0.81 | KDM4E (0.46) | KMT2AUSP2PARP1ALDH1A1NAMPT | |
| SCHEMBL13713105 | 0.76 | L3MBTL1 (0.50) | KMT2AUSP2ALDH1A1TSHRROCK1 | |
| SCHEMBL1156952 | 0.74 | DRD2 (0.47) | CYP3A4CYP17A1CYP11B1CYP11B2CYP2C9 | |
| SCHEMBL27781473 | 0.71 | AURKA (0.66) | CYP3A4KMT2AALDH1A1HPGDNAMPT | |
| SCHEMBL3068393 | 0.69 | CES2 (0.74) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL17526273 | 0.69 | CES2 (0.56) | CYP2C9CYP2D6CYP1A2CYP2C19KMT2A | |
| SCHEMBL27736020 | 0.68 | TAAR1 (0.57) | CYP3A4CYP17A1CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL1501342 | 0.68 | CYP11B1 (0.69) | CYP3A4CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL11172229 | 0.68 | CES2 (0.50) | KMT2ACES2CES1PARP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242753-B1 | OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8809379-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8735399-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8362022-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110105526-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110034517-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20090197898-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009091759-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091760-A1 | OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | CYP3A4 726/4885CYP17A1 740/4885CYP11B1 192/4885 |
| US-20110034517-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | CYP3A4 760/4885CYP17A1 786/4885CYP11B1 205/4885 |
| US-20110105526-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | CYP3A4 1018/4885CYP17A1 1598/4885CYP11B1 280/4885 |
| US-20090197898-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | CYP3A4 760/4885CYP17A1 786/4885CYP11B1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.